Fate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
FATE Nasdaq 2834 www.fatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jul 3rd, 2025 11:05 am
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Jun 12th, 2025 9:30 am
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - Jun 11th, 2025 7:00 am
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Jun 10th, 2025 8:23 am
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - May 30th, 2025 2:30 pm
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases - May 28th, 2025 9:46 pm
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - May 28th, 2025 3:54 pm
Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - May 15th, 2025 4:13 am
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - May 14th, 2025 9:41 am
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - May 13th, 2025 3:15 pm
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - May 13th, 2025 2:01 pm
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - Apr 29th, 2025 7:25 am
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Apr 27th, 2025 7:34 am
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - Apr 15th, 2025 8:42 am
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - Apr 14th, 2025 6:00 am
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - Apr 4th, 2025 9:30 am
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Mar 8th, 2025 5:46 am
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Mar 6th, 2025 7:04 am
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - Mar 5th, 2025 3:10 pm
Fate Therapeutics: Q4 Earnings Snapshot - Mar 5th, 2025 2:12 pm